Research programme: vitiligo therapy - BTG/King's College LondonAlternative Names: Cyclohexylpiperine - BTG; Piperine - BTG; Piperine analogues - BTG; Tetrahydropiperine - BTG; Vitiligo therapy research programme - BTG/King's College London
Latest Information Update: 07 May 2007
At a glance
- Originator BTG; Kings College London
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Vitiligo
Most Recent Events
- 07 May 2007 No development reported - Preclinical for Vitiligo in United Kingdom (unspecified route)
- 05 Mar 2004 Preclinical trials in Vitiligo in United Kingdom (unspecified route)
- 05 Mar 2004 Piperine-based compounds are available for licensing (http://www.btgplc.com)